title: [Influence of tetrandrine on SORCIN gene expression in K562/A02 cell line].
abstract: This study was aimed to explore the changes of soluble resistance-related calcium binding protein (sorcin) expression in reversion of multidrug resistance of K562/A02 leukemic cell line with different concentrations of tetrandrine (Tet), so as to provide a new theoretic evidence for clinical application of Tet. The inhibition of K562/A02 cell line by daunorubicin (DNR) was assayed by MTT method. The changes of SORCIN gene expression were assayed by RT-PCR. The changes of SORCIN protein expressed were assayed by Western blot. The results showed that Tet could enhance the cytotoxicity of DNR to K562/A02 cells (the IC(50) of DNR + Tet was 11.3+/-0.17 mg/L, 5.15+/-0.10 mg/L, 3.91+/-0.06 mg/L, and 2.52+/-0.04 mg/L, when concentrations of Tet were 0 mg/L, 0.5 mg/L, 1.0 mg/L, and 2.0 mg/L respectively). The gene encoding sorcin was highly expressed in K562/A02 cells, the expression of which was firstly enhanced in Tet concentration 0.5 mg/L, then attenuated in Tet concentration of 1.0, 2.0 mg/L (p<0.05). Sorcin protein expressed lowly in K562 cells and highly in K562/A02 cells, but the expression of SORCIN protein in K562/A02 cells was enhanced in Tet concentration of 0.5 mg/L, then was attenuated in Tet concentration of 1.0, 2.0 mg/L (p<0.05). It is concluded that the effect of Tet on reversal of K562/A02 drug-resistance shows concentration dependence by MTT assay. Tet reverses multidrug-resistance of K562/A02 cells through regulation of expression of SORCIN gene and protein, but not fully correlates to the reversing effect.
authors.affiliation: Department of Hematology, Zhongda Hospital, Southeast University, Nanjing 210009, Jiangsu Province, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Li
authors.forename: Bao-An
authors.initials: BA
authors.lastname: Chen
authors.forename: Min-Sheng
authors.initials: MS
authors.lastname: Zhu
authors.forename: Fen
authors.initials: F
authors.lastname: Gao
authors.forename: Jia-Hua
authors.initials: JH
authors.lastname: Ding
authors.forename: Chong
authors.initials: C
authors.lastname: Gao
authors.forename: Yun-Yu
authors.initials: YY
authors.lastname: Sun
authors.forename: Jian
authors.initials: J
authors.lastname: Cheng
authors.forename: Jun
authors.initials: J
authors.lastname: Wang
authors.forename: Gang
authors.initials: G
authors.lastname: Zhao
authors.forename: Hui-Hui
authors.initials: HH
authors.lastname: Song
authors.forename: Yan
authors.initials: Y
authors.lastname: Ma
authors.forename: Wen
authors.initials: W
authors.lastname: Bao
authors.forename: Xin-Cheng
authors.initials: XC
authors.lastname: Sun
authors.forename: Hong-Yan
authors.initials: HY
authors.lastname: Cheng
authors.forename: Wen-Lin
authors.initials: WL
authors.lastname: Xu
authors.forename: Hui-Ling
authors.initials: HL
authors.lastname: Shen
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D044182:Benzylisoquinolines / Q000494:pharmacology*; D002135:Calcium-Binding Proteins / Q000235:genetics / Q000378:metabolism*; D004317:Doxorubicin; D018432:Drug Resistance, Multiple / Q000187:drug effects*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D006801:Humans; D020014:K562 Cells
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D044182:Benzylisoquinolines; D002135:Calcium-Binding Proteins; C503113:SRI protein, human; C009438:tetrandrine; D004317:Doxorubicin